Management Team

Bent U. Frandsen, Chief Executive Officer

Bent Frandsen holds a MSc in Finance and Strategic Planning from Copenhagen Business School, Denmark.

He has more than 27 years of professional experience in management, finance, and business development positions in multinational companies, including more than 24 years life science experience at public listed companies: Lundbeck, ALK-Abelló, Coloplast, and private companies: NsGene, CMC Biologics, and Amphidex.

He is experienced in licensing, services, M&A, and new cash deals in excess of €200 million, and has furthermore been in charge of successfully closing numerous collaboration agreements pertaining to research and development of both new chemical entities and biologicals.

Bent Frandsen is employed since 2016 and was appointed CEO in 2019. He entered the board of AdaptVac ApS in 2017.

Shares: 70,051

Warrants: 32,094

Wian de Jongh, CSO and co-founder

Dr. de Jongh has a MSc (cum laude) in Chemical Engineering from the University of Stellenbosch, South Africa and holds a PhD in Biotechnology from the Technical University of Denmark. He was furthermore awarded an affiliated associate professorship at DTU in 2017.

Dr. de Jongh is an expert within advanced cell line genetic engineering and applied metabolic engineering targeting improved production characteristics. Dr. de Jongh has significant experience from the pharmaceutical industry within molecular biology, cell line development, project management, upstream process development, process scale-up, regulatory systems and transfer to cGMP manufacturing.

Dr. de Jongh was instrumental in the development of the ExpreS2 technology. He has served on the steering committee and as project manager on several larger grant-funded projects. Dr. de Jongh is employed since 2011. In addition, he is the acting CEO and board member of AdaptVac ApS since 2017. Dr. de Jongh is co-founder of ExpreS2ion Biotechnologies ApS.

Shares: Dr. de Jongh owns 32.22% of the founder owned company ExpreS2ion Holding ApS, which owns 1,744,370 (10.83%) of the shares in ExpreS2ion Biotech Holding AB. In addition, Dr. de Jongh privately owns 43,600 shares in ExpreS2ion Biotech Holding AB.

Warrants:  32,094

Keith Alexander, Chief Financial Officer

Keith Alexander holds an MBA from The Wharton School of the University of Pennsylvania, and a B.Sc. in Industrial Management, with a minor in Biological Sciences, from Purdue University.

He has over 20 years of professional experience in investment markets, investor communications, corporate strategy, and business development from American and Danish banks. Over his career, he has served in leadership, analytical and commercial functions at J.P. Morgan Securities and J.P. Morgan Asset Management in NYC, NY, USA, Danske Bank Asset Management (formerly Danske Capital) in Kongens Lyngby, Denmark and Accenture (formerly Andersen Consulting) in Chicago, IL, USA.

Keith has contributed to raising over €1 billion for equity and bond portfolios, evaluated large M&A transactions, structured and valued cross-border joint ventures, advised investors managing over $8 trillion in assets, and analyzed financial services companies as a member of the #1 ranked All-American Equity Research Team in 2010 at J.P. Morgan Securities.

Keith Alexander is employed since October 2020 and is an American citizen with Danish permanent residence.

Shares: 0

Warrants: 0